July 24, 2019 | City of Hope
An study conducted by Michael Caligiuri, M.D., and Jianhua Yu, Ph.D., unveiled why anti-PD-L1 monoclonal antibodies (mAb) are still effective in fighting tumors that lack PD-L1 receptors on their cells.
First-of-its-kind CAR T clinical trial enrolls HER2+ breast cancer patients with brain metastases
October 30, 2018 | City of Hope
City of Hope is now enrolling patients in a phase 1 trial evaluating the safety and efficacy of CAR T cell therapy in patients with HER2+ breast cancer that has metastasized to the brain.
Groundbreaking new CAR T cell trial opens for patients with breast cancer that has spread to the brain
October 30, 2018 | Letisia Marquez
A new City of Hope chimeric antigen receptor (CAR) T cell trial – the first to focus on HER2-postive breast cancer patients with brain metastases – is now enrolling potential participants.
A triple-negative breast cancer trial has its first success story
October 12, 2018 | Maxine Nunes
Linda Collins's outlook was bleak, thanks to her triple-negative breast cancer diagnosis, until City of Hope oncologist Yuan Yuan, M.D., Ph.D. helped develop a revolutionary new trial to help her.
City of Hope posts higher breast cancer survival rates at all stages
October 9, 2018 | City of Hope
City of Hope is proud of having higher survival rates at all stages of breast cancer than those of the Los Angeles Registry of the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program.
New hormone and immunotherapy trial for breast cancer patients
October 8, 2018 | City of Hope
This phase 2 trial studies the side effects and how well pembrolizumab and enobosarm work in treating patients with androgen receptor positive triple-negative breast cancer that has spread to other places in the body.
Patients over 60 needed for HER2-positive breast cancer study
October 7, 2018 | City of Hope
Researchers are actively recruiting for patients 60 years and older for a phase 2 trial studying the side effects of and how well neratinib works in treating older patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer that has spread from where it started to other places in the body.